Share price of Burlington, MA-based LeMaitre Vascular, Inc. (LMAT - Free Report) reached a new 52-week high of $21.20 on Sep 13, eventually closing a bit lower at $20.39.
Notably, this represents a promising one-year return of approximately 45%, much better than the S&P 500’s 7.5% over the same time frame.
Meanwhile, we note that LeMaitre holds a Zacks Rank #2 (Buy). The stock has a market cap of $389.9 million and an impressive long-term expected earnings growth rate of 15%.
Growth Catalysts
LeMaitre’s strong international foothold is a significant catalyst in our view. Notably, the company has initiated its operations in the countries of Madrid, Toronto, Melbourne and Shanghai in the just-reported second-quarter of fiscal 2016. On this regard we note LeMaitre registered 22% growth in its international operations on a year-over-year basis in the quarter.
The current strength in LeMaitre’s market position is very encouraging, courtesy of its flagship XenoSure, which registered 36% year-over-year growth in the reported quarter. In fact, the company’s entire biologic portfolio holds considerable promise, which consists of the Omniflow graft and the recently acquired ProCol graft that have strengthened the company’s foothold in the market.
On this regard, a glimpse at the second-quarter results reveals an impressive quarter for LeMaitre. Notably, adjusted earnings of 14 cents per share comfortably beat the Zacks Consensus Estimate by 3 cents. However, revenues of nearly $22 million were in line with the consensus mark.
LeMaitre, with its set of innovative product line, is a prominent player in the huge and growing peripheral vascular market. This niche market is expected to grow at a CAGR of 6.8% and reach $3.4 billion by 2022 globally, as per GlobalData. Buoyed by such optimistic trends, the company is expected to enhance its growth trajectory in the long haul.
Estimate Revisions
The Zacks Consensus Estimate for fiscal 2016 inched up by a penny to 55 cents over the last 30 days. Similarly, fiscal 2017 estimates increased by a penny to 63 cents over the same time frame.
Other Key Picks
Other favorably ranked stocks in the broader medical sector include IDEXX Laboratories Inc. (IDXX - Free Report) , Masimo Corporation (MASI - Free Report) and Lantheus Holdings Inc. (LNTH - Free Report) . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Share price of Burlington, MA-based LeMaitre Vascular, Inc. (LMAT - Free Report) reached a new 52-week high of $21.20 on Sep 13, eventually closing a bit lower at $20.39.
Notably, this represents a promising one-year return of approximately 45%, much better than the S&P 500’s 7.5% over the same time frame.
Meanwhile, we note that LeMaitre holds a Zacks Rank #2 (Buy). The stock has a market cap of $389.9 million and an impressive long-term expected earnings growth rate of 15%.
Growth Catalysts
LeMaitre’s strong international foothold is a significant catalyst in our view. Notably, the company has initiated its operations in the countries of Madrid, Toronto, Melbourne and Shanghai in the just-reported second-quarter of fiscal 2016. On this regard we note LeMaitre registered 22% growth in its international operations on a year-over-year basis in the quarter.
The current strength in LeMaitre’s market position is very encouraging, courtesy of its flagship XenoSure, which registered 36% year-over-year growth in the reported quarter. In fact, the company’s entire biologic portfolio holds considerable promise, which consists of the Omniflow graft and the recently acquired ProCol graft that have strengthened the company’s foothold in the market.
On this regard, a glimpse at the second-quarter results reveals an impressive quarter for LeMaitre. Notably, adjusted earnings of 14 cents per share comfortably beat the Zacks Consensus Estimate by 3 cents. However, revenues of nearly $22 million were in line with the consensus mark.
LeMaitre, with its set of innovative product line, is a prominent player in the huge and growing peripheral vascular market. This niche market is expected to grow at a CAGR of 6.8% and reach $3.4 billion by 2022 globally, as per GlobalData. Buoyed by such optimistic trends, the company is expected to enhance its growth trajectory in the long haul.
Estimate Revisions
The Zacks Consensus Estimate for fiscal 2016 inched up by a penny to 55 cents over the last 30 days. Similarly, fiscal 2017 estimates increased by a penny to 63 cents over the same time frame.
Other Key Picks
Other favorably ranked stocks in the broader medical sector include IDEXX Laboratories Inc. (IDXX - Free Report) , Masimo Corporation (MASI - Free Report) and Lantheus Holdings Inc. (LNTH - Free Report) . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on MASI - FREE
Get the latest research report on IDXX - FREE
Get the latest research report on LMAT - FREE
Get the latest research report on LNTH - FREE